Buyer

AOK SACHSEN ANHALT

Opportunities

No declared value on record

A Germany buyer, with 8 published contracts, most recently 10 months ago.

Germany

Opportunities

No declared value on record

Contract history

8 entries

Most recent
7 Dec 2025
10 months ago
Biggest
—
Value not disclosed
Average size
—
Value not disclosed
Last 12 months
2
entries

Published · 8

May 25Jul 25Aug 25Oct 25Dec 25

Opportunities

Showing open · 7

Healthcare & MedicalGermany

Germany – Timolol Medication Contracts

This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join

AOK SACHSEN ANHALT

Published 7 Dec 2025

Healthcare & MedicalGermany

Germany – Medicines – Medicines with the Active Ingredient Abaloparatide (ATC: H05AA04)

This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all

AOK SACHSEN ANHALT

Published 18 Nov 2025

Healthcare & MedicalGermany

Rivaroxaban Drug Supply Contracts

This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph

AOK SACHSEN ANHALT

Published 25 Aug 2025

Healthcare & MedicalGermany

Germany – Medicines – Medicines Containing Tramadol and Paracetamol

This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent

AOK SACHSEN ANHALT

Published 13 Jul 2025

Healthcare & MedicalGermany

Procurement of Nilotinib Medicines

This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredient Nilotinib (ATC: L01EA03) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join

AOK SACHSEN ANHALT

Published 17 Jun 2025

Healthcare & MedicalGermany

Axitinib Drug Supply Contracts

This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Axitinib (ATC: L01EK01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or

AOK SACHSEN ANHALT

Published 18 May 2025

Healthcare & MedicalGermany

Germany – Medicines – Medicines containing the active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57)

This publication is about entering into non-exclusive discount contracts according to § 130c Abs. 1 SGB V in conjunction with § 130a Abs. 8 SGB V for finished medicinal products containing the active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57) as part of an "open-house model". Under unif

AOK SACHSEN ANHALT

Published 18 May 2025